Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
Dyne Therapeutics (Nasdaq: DYN), a clinical-stage company developing therapeutics for genetically driven neuromuscular diseases, has granted inducement equity awards to its new Chief Financial Officer, Erick J. Lucera. The awards include:
- A non-statutory stock option to purchase 214,500 shares at the March 31, 2025 closing price
- A restricted stock unit (RSU) award for 66,100 shares
The stock option has a 10-year term with a 4-year vesting schedule: 25% vesting on March 31, 2026, and the remainder in quarterly installments over three years. The RSU award vests in equal annual installments over four years, starting March 31, 2026. Both awards are contingent on Mr. Lucera's continued service and were granted under Dyne's 2024 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Dyne Therapeutics (Nasdaq: DYN), un'azienda in fase clinica che sviluppa terapie per malattie neuromuscolari di origine genetica, ha concesso premi azionari di indennizzo al suo nuovo Direttore Finanziario, Erick J. Lucera. I premi includono:
- Un'opzione su azioni non statutaria per l'acquisto di 214.500 azioni al prezzo di chiusura del 31 marzo 2025
- Un premio in azioni vincolate (RSU) per 66.100 azioni
L'opzione su azioni ha un termine di 10 anni con un programma di maturazione di 4 anni: il 25% matura il 31 marzo 2026 e il resto in rate trimestrali nel corso di tre anni. Il premio RSU matura in rate annuali uguali nel corso di quattro anni, a partire dal 31 marzo 2026. Entrambi i premi sono subordinati al servizio continuato del signor Lucera e sono stati concessi nell'ambito del Piano di Incentivi Azionari di Indennizzo 2024 di Dyne, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Dyne Therapeutics (Nasdaq: DYN), una empresa en etapa clínica que desarrolla terapias para enfermedades neuromusculares de origen genético, ha otorgado premios de acciones de incentivo a su nuevo Director Financiero, Erick J. Lucera. Los premios incluyen:
- Una opción de compra de acciones no estatutaria para adquirir 214,500 acciones al precio de cierre del 31 de marzo de 2025
- Un premio de unidades de acciones restringidas (RSU) por 66,100 acciones
La opción de compra tiene un plazo de 10 años con un calendario de adquisición de 4 años: el 25% se adquiere el 31 de marzo de 2026, y el resto en cuotas trimestrales durante tres años. El premio RSU se adquiere en cuotas anuales iguales durante cuatro años, comenzando el 31 de marzo de 2026. Ambos premios están condicionados al servicio continuo del Sr. Lucera y se otorgaron bajo el Plan de Incentivos de Acciones de Inducción 2024 de Dyne, cumpliendo con la Regla de Cotización Nasdaq 5635(c)(4).
다인 테라퓨틱스(Dyne Therapeutics, Nasdaq: DYN)는 유전적 원인으로 발생하는 신경근육 질환을 치료하기 위한 치료제를 개발하는 임상 단계의 회사로, 새로운 최고재무책임자(CFO)인 에릭 J. 루세라(Erick J. Lucera)에게 유인 주식 보상을 부여했습니다. 보상에는 다음이 포함됩니다:
- 2025년 3월 31일 종가로 214,500주를 구매할 수 있는 비법정 주식 옵션
- 66,100주에 대한 제한된 주식 단위(RSU) 보상
주식 옵션은 10년 기간을 가지며, 4년의 분할 일정이 있습니다: 2026년 3월 31일에 25%가 분할되고 나머지는 3년에 걸쳐 분기별로 지급됩니다. RSU 보상은 2026년 3월 31일부터 시작하여 4년에 걸쳐 매년 동일한 비율로 분할됩니다. 두 보상은 루세라 씨의 지속적인 서비스에 따라 달라지며, 다인의 2024 유인 주식 인센티브 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)를 준수합니다.
Dyne Therapeutics (Nasdaq: DYN), une entreprise en phase clinique développant des thérapies pour des maladies neuromusculaires d'origine génétique, a accordé des attributions d'actions d'incitation à son nouveau directeur financier, Erick J. Lucera. Les attributions comprennent :
- Une option d'achat d'actions non statutaire pour l'achat de 214 500 actions au prix de clôture du 31 mars 2025
- Une attribution d'unités d'actions restreintes (RSU) pour 66 100 actions
L'option d'achat a une durée de 10 ans avec un calendrier d'acquisition de 4 ans : 25 % sont acquises le 31 mars 2026, et le reste en versements trimestriels sur trois ans. L'attribution RSU s'acquiert en versements annuels égaux sur quatre ans, à partir du 31 mars 2026. Les deux attributions sont conditionnées à la poursuite du service de M. Lucera et ont été accordées dans le cadre du Plan d'Incitation aux Actions d'Indemnisation 2024 de Dyne, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
Dyne Therapeutics (Nasdaq: DYN), ein Unternehmen in der klinischen Phase, das Therapeutika für genetisch bedingte neuromuskuläre Erkrankungen entwickelt, hat seinem neuen Finanzvorstand, Erick J. Lucera, Anreiz-Aktienvergaben gewährt. Die Vergaben umfassen:
- Eine nicht-statutäre Aktienoption zum Kauf von 214.500 Aktien zum Schlusskurs am 31. März 2025
- Eine Auszeichnung in Form von Restricted Stock Units (RSUs) für 66.100 Aktien
Die Aktienoption hat eine Laufzeit von 10 Jahren mit einem Vesting-Zeitplan von 4 Jahren: 25% vesten am 31. März 2026, der Rest in vierteljährlichen Raten über drei Jahre. Die RSU-Auszeichnung vestet in gleichen jährlichen Raten über vier Jahre, beginnend am 31. März 2026. Beide Auszeichnungen sind von der fortgesetzten Dienstzeit von Herrn Lucera abhängig und wurden im Rahmen des Aktienanreizplans 2024 von Dyne gewährt, der der Nasdaq-Listing-Regel 5635(c)(4) entspricht.
- Successful recruitment of new CFO with competitive equity compensation package
- Long-term retention incentives through 4-year vesting schedule
- Potential future shareholder dilution from 280,600 total shares in equity awards
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J. Lucera. The awards were approved by the Compensation Committee of Dyne and made as an inducement material to Mr. Lucera’s acceptance of employment with Dyne under Dyne’s 2024 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement equity awards were granted to Mr. Lucera effective as of March 31, 2025 and consists of a non-statutory stock option to purchase up to 214,500 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on March 31, 2025, and a restricted stock unit award with respect to 66,100 shares of Dyne’s common stock. The stock option award has a ten-year term and is scheduled to vest over four years, with
The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.
About Dyne Therapeutics
Dyne Therapeutics is discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE™ platform, Dyne is developing targeted therapeutics that deliver to muscle and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
What equity compensation package did Dyne Therapeutics (DYN) offer to its new CFO?
How are the stock options structured in DYN's CFO compensation package?
What is the vesting schedule for DYN's CFO restricted stock units?
Under which regulatory framework did DYN grant the CFO equity awards?
